Skip to main content
. 2022 Nov 15;14(11):7831–7841.

Table 3.

Multiple patterns of resistance of H. pylori strains to all tested antibiotics

Resistance Profiles, N (%) Untreated group Re-treated group Recurrence group All P (untreated vs re-treated)
n = 1014 n = 98 n = 4 n = 1116
All susceptible 151 (14.9) 2 (2.0) 0 153 (13.7) 0.001
Mono resistance 484 (47.7) 26 (26.5) 1 (25.0) 511 (44.8) 0.01
    MNZ 429 (42.3) 20 (20.4) 1 (25.0) 450 (40.3) 0.01
    CAM 26 (2.6) 6 (6.1) 0 32 (2.9) 0.090
    LVX 28 (2.8) 0 0 28 (2.5) 0.184
Dual resistance 277 (27.3) 35 (35.7) 2 (50.0) 314 (28.1) 0.077
    CAM+MNZ 102 (10.1) 25 (25.5) 2 (50.0) 129 (11.6) 0.01
    LVX+MNZ 160 (15.8) 9 (9.2) 0 169 (15.1) 0.082
    CAM+LVX 12 (1.2) 1 (1.0) 0 13 (1.2) 1.00
    FUR+LVX 3 (0.3) 0 0 3 (0.3) 1.00
Triple resistance 102 (10.1) 34 (34.7) 1 (25.0) 137 (12.3) 0.01
    CAM+LVX+MNZ 99 (9.8) 34 (34.7) 1 (25.0) 134 (12.0) 0.01
    LVX+FUR+MNZ 2 (0.2) 0 0 2 (0.2) 1.00
    CAM+TCN+MNZ 1 (0.1) 0 0 1 (0.1) 1.00
Quadruple resistance 0 1 (1.0) 0 1 (0.1) 0.004
    CAM+LVX+AMX+MNZ 0 1 (1.0) 0 1 (0.1) 0.004

AMX, amoxicillin; CAM, clarithromycin; LEV, levofloxacin; MNZ, metronidazole; TCN, tetracycline; FUR, furazolidone.